The neutralizing human recombinant antibodies to pathogenic Orthopoxviruses derived from a phage display immune library

Virus Research

Volumn 163, Issue 1, 2012, Pages 141-150

  Tikunova, Nina ^a   Dubrovskaya, Viktoriya ^b   Morozova, Vera ^a   Yun, Tatiana ^a   Khlusevich, Yana ^b   Bormotov, Nikolai ^b   Laman, Aleksandr ^c   Brovko, Fedor ^c   Shvalov, Aleksandr ^b   Belanov, Eugeni ^b  

^a INSTITUTE OF CHEMICAL BIOLOGY AND FUNDAMENTAL MEDICINE   (Russian Federation)

^b STATE RESEARCH CENTER OF VIROLOGY AND BIOTECHNOLOGY VECTOR   (Russian Federation)

^c SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

Author keywords

Cowpox virus; Fully human mAb; Monkeypox virus; Neutralization; Phage display; ScFv; Vaccinia virus

Indexed keywords

MONOCLONAL ANTIBODY; NEUTRALIZING ANTIBODY; RECOMBINANT ANTIBODY; RECOMBINANT PROTEIN; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; VACCINIA VACCINE; VIRUS ANTIBODY; VIRUS PROTEIN;

ANTIBODY LIBRARY; ANTIGEN RECOGNITION; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; COWPOX VIRUS; DOSE RESPONSE; HUMAN; HUMAN CELL; IMMUNIZATION; MOLECULAR CLONING; MONKEYPOX VIRUS; NORMAL HUMAN; ORTHOPOXVIRUS; PERIPHERAL LYMPHOCYTE; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN TARGETING; VACCINIA VIRUS; VIRUS NEUTRALIZATION; VIRUS VIRULENCE; WESTERN BLOTTING;

ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; ANTIBODY AFFINITY; BLOTTING, WESTERN; HUMAN EXPERIMENTATION; HUMANS; KINETICS; MOLECULAR SEQUENCE DATA; NEUTRALIZATION TESTS; ORTHOPOXVIRUS; PEPTIDE LIBRARY; PROTEIN BINDING; SEQUENCE ANALYSIS, DNA; SINGLE-CHAIN ANTIBODIES; SMALLPOX VACCINE; VIRAL PLAQUE ASSAY; VIRAL PROTEINS;

COWPOX VIRUS; MONKEYPOX VIRUS; VACCINIA VIRUS;

EID: 84855610348     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2011.09.008     Document Type: Article

References (49)

1. Alkhalil A., Strand A., Mucker E., Huggins J.W., Jahrling P.B., Ibrahim S.W. Inhibition of Monkeypox virus replication by RNA interference. Virol. J. 2009, 6:188-198.
2. Baker R.O., Bray M., Huggins J.W. Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections. Antiviral Res. 2003, 57:13-23.
3. Beatty J.D., Beatty B.G., Vlahos W.G. Measurement of monoclonal antibody affinity by non-competitive enzyme immunoassay. J. Immunol. Methods 1987, 100:173-179.
4. Benhnia M.R., McCausland M.M., Su H.P., Singh K., Hoffmann J., Davies D.H., Felgner P.L., Head S., Sette A., Garboczi D.N., Crotty S. Redundancy and plasticity of neutralizing antibody responses are cornerstone attributes of the human immune response to the smallpox vaccine. J. Virol. 2008, 82:3751-3768.
5. Chen Z., Earl P., Americo J., Damon I., Smith S.K., Zhou Y.H., Yu F., Sebrell A., Emerson S., Cohen G., Eisenberg R.J., Svitel J., Schuck P., Satterfield W., Moss B., Purcell R. Chimpanzee/human mAbs to vaccinia virus B5 protein neutralize vaccinia and smallpox viruses and protect mice against vaccinia virus. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:1882-1887.
6. Chen Z., Earl P., Americo J., Damon I., Smith S.K., Yu F., Sebrell A., Emerson S., Cohen G., Eisenberg R.J., Gorshkova I., Schuck P., Satterfield W., Moss B., Purcell R. Characterization of chimpanzee/human monoclonal antibodies to vaccinia virus A33 glycoprotein and its variola virus homolog in vitro and in a vaccinia virus mouse protection model. J. Virol. 2007, 81:8989-8995.
7. Davies D.H., McCausland M.M., Valdez C., Huynh D., Hernandez J.E., Mu Y., Hirst S., Villarreal L., Felgner P.L., Crotty S. Vaccinia virus H3L envelope protein is a major target of neutralizing antibodies in humans and elicits protection against lethal challenge in mice. J. Virol. 2005, 79:11724-11733.
8. Demkowicz W.E., Maa J.S., Esteban M. Identification and characterization of Vaccinia virus genes encoding proteins that are highly antigenic in animals and are immunodominant in vaccinated humans. J. Virol. 1992, 70:2627-2631.
9. Dubrovskaia V.V., Ulitin A.B., Gileva I.P.L.A.G., Ilyichev A.A.B.N.I., Brovko F.A., Shchelkunov S.N., Belanov E.F., Tikunova N.V. Construction of combinatorial immune library of human single chain antibodies to Orthopoxviruses and selection of antibodies to recombinant prA30L of the variola virus. Mol Biol (Mosk). 2007, 41:157-167.
10. Earl P.L., Americo J.L., Wyatt L.S., Eller L.A., Whitbeck J.C., Cohen G.H., Eisenberg R.J., Hartmann C.J., Jackson D.L., Kulesh D.A., Martinez M.J., Miller D.M., Mucker E.M., Shamblin J.D., Zwiers S.H., Huggins J.W., Jahrling P.B., Moss B. Immunogenicity of a highly attenuated MVA smallpox vaccine and protection against monkeypox. Nature 2004, 428:182-185.
11. Earl P.L., Americo J.L., Wyatt L.S., Eller L.A., Montefiori D.C., Byrum R., Piatak M., Lifson J.D., Amara R.R., Robinson H.R., Huggins J.W., Moss B. Recombinant modified vaccinia virus Ankara provides durable protection against disease caused by an immunodeficiency virus as well as long-term immunity to an orthopoxvirus in a non-human primate. Virology 2007, 366:84-97.
12. Frey S.E., Newman F.K., Yan L., Lottenbach K.R., Belshe R.B. Response to smallpox vaccine in persons immunized in the distant past. JAMA 2003, 289:3295-3299.
13. Goncalvez A.P., Chien C.H., Tubthong K., Gorshkova I., Roll C., Donau O., Schuck P., Yoksan S., Wang S.D., Purcell R.H., Lai C.J. Humanized monoclonal antibodies derived from chimpanzee Fabs protect against Japanese encephalitis virus in vitro and in vivo. J. Virol. 2008, 82:7009-7021.
14. Gorny M.K., Wang X.H., Williams C., Volsky B., Revesz K., Witover B., Burda S., Urbanski M., Nyamby Ph., Krachmarov Ch., Pinter A., Zolla-Pazner S., Nadas A. Preferential use of the VH5-51 gene segment by the human immune response to code for antibodies against the V3 domain of HIV-1. Mol. Immunol. 2009, 46:917-926.
15. Gould L.H., Sui J., Foellmer H., Oliphant T., Wang T., Ledizet M., Murakami A., Noonan K., Lambeth C., Kar K., Anderson J.F., de Silva A.M., Diamond M.S., Koski R.A., Marasco W.A., Fikrig E. Protective and therapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus. J. Virol. 2005, 79:14606-14613.
16. Greenberg R.N., Kennedy J.S., Clanton D.J., Plummer E.A., Hague L., Cruz J., Ennis F.A., Blackwelder W.C., Hopkins R.J. Safety and immunogenicity of new cell-cultured smallpox vaccine compared with calf-lymph derived vaccine: a blind, single-centre, randomised controlled trial. Lancet 2005, 365:398-409.
17. Griffiths A.D., Williams S.C., Hartley O., Tomlinson I.M., Waterhouse P., Crosby W.L., Kontermann R.E., Jones P.T., Low N.M., Allison T.J. Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J. 1994, 13:3245-3260.
18. Hooper J.W., Thompson E., Wilhelmsen C., Zimmerman M., Ichou M.A., Steffen S.E., Schmaljohn C.S., Schmaljohn A.L., Jahrling P.B. Smallpox DNA vaccine protects nonhuman primates against lethal monkeypox. J. Virol. 2004, 78:4433-4443.
19. Hopkins R.J., Lane J.M. Clinical efficacy of intramuscular vaccinia immune globulin: a literature review. Clin. Infect. Dis. 2004, 39:819-826.
20. Houimel M., Dellagi K. Isolation and characterization of human neutralizing antibodies to rabies virus derived from a recombinant immune antibody library. J. Virol. Methods 2009, 161:205-215.
21. Hutson C.L., Abel J.A., Carroll D.S., Olson V.A., Braden Z.H., Hughes C.M., Dillon M., Hopkins C., Karem K.L., Damon I.K., Osorio J.E. Comparison of West African and Congo Basin monkeypox viruses in BALB/c and C57BL/6 mice. PLoS One 2009, 5:e8912.
22. Kang X., Yang B.A., Hu Y., Zhao H., Xiong W., Yang Y., Si B., Zhu Q. Human neutralizing Fab molecules against severe acute respiratory syndrome coronavirus generated by phage display. Clin. Vaccine Immunol. 2006, 13:953-957.
23. Kempe C.H., Berge T., England B. Hyperimmune vaccinial gamma globulin: source, evaluation and use in prophylaxis and therapy. Pediatrics 1956, 18:177-188.
24. Levanov L., Matveev L., Goncharova E., Lebedev L., Ryzhikov A., Yun T., Batanova T., Shvalov A., Baykov I., Shingarova L., Kirpichnikov M., Tikunova N. Chimeric antibodies against tick-borne encephalitis virus. Vaccine 2010, 28:4415-4420.
25. Lim A.P., Chan C.E., Wong S.K., Chan A.H., Ooi E.E., Hanson B.J. Neutralizing human monoclonal antibody against H5N1 influenza HA selected from a Fab-phage display library. Virol. J. 2008, 5:80-90.
26. Lin C.L., Chung C.S., Heine H.G., Chang W. Vaccinia virus envelope H3L protein binds to cell surface heparan sulfate and is important for intracellular mature virion morphogenesis and virus infection in vitro and in vivo. J. Virol. 2000, 74:3353-3365.
27. Lustig S., Maik-Rachline G., Paran N., Melamed S., Israely T., Erez N., Orr N., Reuveny S., Ordentlich A., Laub O., Shafferman A., Velan B. Effective post-exposure protection against lethal Orthopoxviruses infection by vaccinia immune globulin involves induction of adaptive immune response. Vaccine 2009, 27:1691-1699.
28. Marennikova S.S., Shchelkunov S.N. Orthopoxviruses Pathogenic for Humans 1998, K{cyrillic}M{cyrillic}K{cyrillic} Scientific Press Ltd., Moscow.
29. Marks J.D., Hoogenboom H.R., Bonnert T.P., McCafferty J., Griffiths A.D., Winter G. By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J. Mol. Biol. 1991, 222:581-597.
30. Marks J.D., Tristem M., Karpas A., Winter G. Oligonucleotide primers for polymerase chain reaction amplification of human immunoglobulin variable genes and design of family-specific oligonucleotide probes. Eur. J. Immunol. 1991, 21:985-991.
31. McCausland M.M., Benhnia M.R., Crickard L., Laudenslager J., Granger S.W., Tahara T., Kubo R., Koriazova L., Kato S., Crotty S. Combination therapy of Vaccinia virus infection with human anti-H3 and anti-B5 monoclonal antibodies in a small animal model. Antivir. Ther. 2010, 15:661-675.
32. Meyer H., Totmenin A., Gavrilova E., Shchelkunov S. Variola and camelpox virus-specific sequences are part of a single large open reading frame identified in two German cowpox virus strains. Virus Res. 2005, 108:39-43.
33. Moss B. Poxviruses. Fields Virology 2007, 2905-2945. Lippincott Williams & Wilkins Publishers, Philadelphia. fifth ed. D.M. Knipe, P.M. Howley (Eds.).
34. Nahary L., Trahtenherts A., Benhar I. Isolation of scFvs that inhibit the NS3 protease of hepatitis C virus by a combination of phage display and a bacterial genetic screen. Methods Mol. Biol. 2009, 562:115-132.
35. Nissim A., Hoogenboom H.R., Tomlinson I.M., Flynn G., Midgley C., Lane D., Winter G. Antibody fragments from a 'single pot' phage display library as immunochemical reagents. EMBO J. 1994, 13:692-698.
36. Ohta A., Fujita A., Murayama T., Iba Y., Kurosawa Y., Yoshikawa T., Asano Y. Recombinant human monoclonal antibodies to human cytomegalovirus glycoprotein B neutralize virus in a complement-dependent manner. Microbes Infect. 2009, 11:1029-1036.
37. Parker S., Handley L., Buller R.M. Therapeutic and prophylactic drugs to treat orthopoxvirus infections. Future Virol. 2008, 3:595-612.
38. Pütz M.M., Midley C.M., Law M., Smith G.M. Quantification of antibody responses against multiple antigens of the two infectious forms of Vaccinia virus provides a benchmark for smallpox vaccinations. Nat. Med. 2006, 74:3525-3536.
39. Reading S.A., Dimmock N.J. Neutralization of animal virus infectivity by antibody. Arch. Virol. 2007, 152:1047-1059.
40. Reed K.D., Melski J.W., Graham M.B., Regnery R.L., Sotir M.J., Wegner M.V., Kazmierczak J.J., Stratman E.J., Li Y., Fairley J.A., Swain G.R., Olson V.A., Sargent E.K., Kehl S.C., Frace M.A., Kline R., Foldy S.L., Davis J.P., Damon I.K. The detection of monkeypox in humans in the western hemisphere. N. Engl. J. Med. 2004, 350:342-350.
41. Seaman M.S., Wilck M.B., Baden L.R., Walsh S.R., Grandpre L.E., Devoy C., Giri A., Noble L.C., Kleinjan J.A., Stevenson K.E., Kim H.T., Dolin R. Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax. J. Infect. Dis. 2010, 201:1353-1360.
42. Sejvar J.J., Chowdary Y., Schomogyi M., Stevens J., Patel J., Karem K., Fischer M., Kuehnert M.J., Zaki S.R., Paddock C.D., Guarner J., Shieh W.J., Patton J.L., Bernard N., Li Y., Olson V.A., Kline R.L., Loparev V.N., Schmid D.S., Beard B., Regnery R.R., Damon I.K. Human monkeypox infection: a family cluster in the midwestern United States. J. Infect. Dis. 2004, 190:1833-1840.
43. Schmaljohn C., Cui Y., Kerby S., Pennock D., Spik K. Production and characterization of human monoclonal antibody Fab fragments to vaccinia virus from a phage-display combinatorial library. Virology 1999, 258:189-200.
44. Tikunova N.V., Bovshik E.I., Iun T.E., Zhirakovskaya E.V., Morozova V.V., Batanova T.A., Gus'kov A.A., Sokunova E.B., Ilyichev A.A., Sandakhchiev L.S. Human recombinant antibodies to variola virus. Vopr. Virusol. 2005, 50:20-25.
45. Von Krempelhuber A., Vollmar J., Pokorny R., Rapp P., Wulff N., Petzold B., Handley A., Mateo L., Siersbol H., Kollaritsch H., Chaplin P. A randomized, double-blind, dose-finding Phase II study to evaluate immunogenicity and safety of the third generation smallpox vaccine candidate IMVAMUNE. Vaccine 2010, 28:1209-1216.
46. Weitkamp J.H., Kallewaard N., Kusuhara K., Bures E., Williams J.V., LaFleur B., Greenberg H.B., Crowe J.E. Infant and adult human B cell responses to rotavirus. Share common immunodominant variable gene repertoires. J. Immunol. 2003, 171:4680-4688.
47. Williams J.V., Chen Z., Cseke G., Wright D.W., Keefer C.J., Tollefson S.J., Hessell A., Podsiad A., Shepherd B.E., Sanna P.P., Burton D.R., Crowe J.E., Williamson R.A. A recombinant human monoclonal antibody to human metapneumovirus fusion protein that neutralizes virus in vitro and is effective therapeutically in vivo. J. Virol. 2007, 81:8315-8324.
48. Xiao Y., Isaacs S. Therapeutic vaccines and antibodies for treatment of orthopoxvirus infections. Viruses 2010, 2:2381-2403.
49. Yang G., Pevear D.C., Davies M.H., Collett M.S., Bailey T., Rippen S., Barone L., Burns C., Rhodes G., Tohan S., Huggins J.W., Baker R.O., Buller R.L., Touchette E., Waller K., Schriewer J., Neyts J., DeClercq E., Jones K., Hruby D., Jordan R. An orally bioavailable antipoxvirus compound (ST-246) inhibits extracellular virus formation and protects mice from lethal orthopoxvirus challenge. J. Virol. 2005, 79:13139-13149.